Please select the option that best describes you:

Do you regularly perform pharmacogenomic testing for patients prior to starting chemotherapy?  

For either patients in general or for patients who will receive regimens with well-described toxicities such as irinotecan/UGT1A1.

If so, do you request testing for specific genes, or do you typically request a panel?



Answer from: Medical Oncologist at Community Practice
Comments
Medical Oncologist at NYU Winthrop Hospital
Good for academic centers, but not practical in a ...
Sign in or Register to read more

Answer from: Medical Oncologist at Community Practice
Sign in or Register to read more

Answer from: Medical Oncologist at Academic Institution
Comments
Medical Oncologist at Dartmouth Cancer Center, Dartmouth-Hitchcock Medical Center
It is worth noting that the great majority of fata...
Sign in or Register to read more

Answer from: Medical Oncologist at Academic Institution
Sign in or Register to read more

Answer from: Medical Oncologist at Community Practice
Sign in or Register to read more